Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IPHA

Innate Pharma ADR

Dec 11 • 04:00PM ET

1.69

Dollar change -0.11
Percentage change -6.11	%

Healthcare • Biotechnology • France • NASD

Peers: BPMC FATE AFMD NKTR PDSB ONCT CTMX IMTX IMUX SWTX

| Held by: CNCR APIE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.46	Insider Own	-	Shs Outstand	80.95M	Perf Week	16.55%
Market Cap	139.90M	Forward P/E	4.12	EPS next Y	0.41	Insider Trans	-	Shs Float	-	Perf Month	-8.65%
Income	-36.81M	PEG	-	EPS next Q	-0.27	Inst Own	0.29%	Short Float	-	Perf Quarter	-25.88%
Sales	26.87M	P/S	5.21	EPS this Y	-137.28%	Inst Trans	-7.50%	Short Ratio	0.28	Perf Half Y	-31.85%
Book/sh	0.38	P/B	4.43	EPS next Y	276.82%	ROA	-19.40%	Short Interest	0.06M	Perf Year	-30.74%
Cash/sh	1.19	P/C	1.42	EPS next 5Y	-	ROE	-78.33%	52W Range	1.29 - 3.15	Perf YTD	-39.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-62.03%	52W High	-46.35%	Beta	0.27
Dividend TTM	-	Quick Ratio	2.92	Sales past 5Y	31.77%	Gross Margin	-	52W Low	31.01%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	2.92	EPS Y/Y TTM	42.43%	Oper. Margin	-191.19%	RSI (14)	50.83	Volatility	12.98% 9.16%
Employees	179	Debt/Eq	1.23	Sales Y/Y TTM	-42.35%	Profit Margin	-136.99%	Recom	1.33	Target Price	7.23
Option/Short	No / No	LT Debt/Eq	0.92	EPS Q/Q	-1590.99%	Payout	-	Rel Volume	1.31	Prev Close	1.80
Sales Surprise	2.50%	EPS Surprise	-13.99%	Sales Q/Q	-76.53%	Earnings	Nov 13 BMO	Avg Volume	227.73K	Price	1.69
SMA20	7.18%	SMA50	-6.49%	SMA200	-24.53%	Trades		Volume	298,413	Change	-6.11%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$7
Dec-15-20	Downgrade	SVB Leerink	Outperform → Mkt Perform	$7 → $5
Nov-24-20	Initiated	Goldman	Neutral	$4.75

Dec-10-24 06:30AM	Innate Pharma SA Reveals Promising Lacutamab Trial Results (TipRanks) -5.26%
Dec-09-24 01:00AM	Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma (Business Wire) +29.25%
Dec-06-24 01:00AM	Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma (Business Wire)
Dec-03-24 01:00AM	Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024 (Business Wire)
Nov-20-24 01:00AM	Innate Pharma Releases Its 2025 Financial Calendar (Business Wire) +13.12%
01:00AM	Loading…
Nov-19-24 01:00AM	Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 (Business Wire)
Nov-13-24 01:00AM	Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results (Business Wire) -11.82%
Nov-08-24 01:00AM	Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 (Business Wire)
Nov-07-24 01:00AM	Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates (Business Wire) -10.45%
Oct-29-24 02:00AM	Innate Pharma Announces Its Participation in Upcoming Investor Conferences (Business Wire) +8.19%
Oct-14-24 01:00AM	Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board (Business Wire)
Sep-30-24 01:00AM	Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024 (Business Wire)
Sep-23-24 01:00AM	Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors (Business Wire)
Sep-12-24 01:00AM	Innate Pharma Reports First Half 2024 Business Update and Financial Results (Business Wire)
Sep-09-24 01:00AM	Innate Pharma SA:Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024 (Business Wire)
01:00AM	Loading…
Sep-05-24 01:00AM	Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update (Business Wire)
Sep-04-24 01:00AM	Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-01-24 01:00AM	Innate Pharma Announces Its Participation in Upcoming Investor Conference (Business Wire)
Jul-25-24 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024 (Business Wire) -7.52%
Jun-18-24 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024 (Business Wire)
Jun-17-24 01:00AM	Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial (Business Wire) -10.64%
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -6.92%
Jun-04-24 01:00AM	Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides (Business Wire) +5.26%
May-28-24 01:00AM	Innate Pharma Announces Its Participation in Upcoming Investor Conferences (Business Wire)
May-24-24 01:00AM	Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting (Business Wire)
May-23-24 04:00PM	Outcome of Innate Pharmas 2024 Annual General Meeting (Business Wire)
May-21-24 01:00AM	Innate Pharma: Clarification Regarding SAR443579 Designation (Business Wire)
May-15-24 01:00AM	Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress (Business Wire) -5.06%
May-14-24 01:00AM	Innate Pharma Reports First Quarter 2024 Business Update and Financial Results (Business Wire)
May-07-24 01:00AM	Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update (Business Wire)
01:00AM	Loading…
Apr-15-24 01:00AM	Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 (Business Wire)
01:00AM	Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients (Business Wire)
Apr-10-24 12:00PM	All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy (Zacks)
01:00AM	Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate (Business Wire)
Apr-09-24 01:00AM	Innate Pharma Announces Its Participation in Upcoming Investor Conference (Business Wire)
Apr-05-24 03:34AM	Innate Pharma Files Its 2023 Universal Registration Document (Document denregistrement Universel) and 2023 Annual Report on Form 20-F (Business Wire)
Mar-22-24 11:33AM	Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 02:00AM	Innate Pharma Reports Full Year 2023 Financial Results and Business Update (Business Wire)
Mar-19-24 02:00AM	Innate Pharma Announces Its Participation to Upcoming Investor Conference (Business Wire)
Mar-14-24 02:00AM	Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results (Business Wire)
Mar-06-24 01:00AM	Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkins Lymphoma (Business Wire)
01:00AM	Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024 (Business Wire)
Feb-21-24 01:00AM	Innate Pharma Announces Its Participation to Upcoming Investor Conference (Business Wire)
Jan-12-24 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024 (Business Wire)
Jan-04-24 01:00AM	Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program (Business Wire)
12:59AM	Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board (Business Wire)
Dec-19-23 01:00AM	Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi (Business Wire) +9.80%
Dec-18-23 01:00AM	Innate Pharma Announces Leadership Change (Business Wire)
Dec-11-23 01:00AM	Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023 (Business Wire) -5.43%
Dec-10-23 01:00AM	Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Szary Syndrome at ASH 2023 (Business Wire)
Nov-27-23 01:00AM	Innate Pharma to Host Virtual KOL Event on Lacutamab (Business Wire)
Nov-15-23 10:36AM	Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 01:00AM	Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update (Business Wire) +13.66%
Nov-07-23 01:00AM	Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update (Business Wire)
Nov-03-23 02:00AM	Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023 (Business Wire) +18.39%
Oct-27-23 01:00AM	Innate Pharma Announces Its Participation to Upcoming Investor Conferences (Business Wire)
Oct-19-23 01:00AM	Innate Pharma 2024 Financial Calendar (Business Wire) -8.78%
Oct-16-23 01:00AM	Innate Pharma Announces Abstracts Selected for ESMO Congress 2023 (Business Wire)
Oct-09-23 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023 (Business Wire)
Oct-05-23 01:00AM	Innate Pharma Provides Update on Lacutamab Clinical Program (Business Wire)
Sep-22-23 01:00AM	Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023 (Business Wire)
Sep-14-23 01:00AM	Innate Pharma Reports First Half 2023 Financial Results and Business Update (Business Wire)
Aug-29-23 01:00AM	Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update (Business Wire)
Aug-10-23 01:00AM	Innate Pharma to Participate in Upcoming Investor Conference (Business Wire)
Jul-11-23 01:00AM	First Patient Dosed in SAR514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma (Business Wire)
Jul-07-23 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023 (Business Wire) +6.12%
Jun-26-23 01:00AM	Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer (Business Wire)
01:00AM	First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer (Business Wire)
Jun-16-23 01:00AM	Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria (Business Wire) +6.75%
Jun-12-23 01:00AM	Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma (Business Wire) +8.36%
Jun-10-23 01:00AM	Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress (Business Wire)
Jun-08-23 01:00AM	SAR579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies (Business Wire) +10.30%
01:00AM	Innate Pharma: SAR579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies (Business Wire)
Jun-07-23 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023 (Business Wire)
May-26-23 01:00AM	Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR579 / IPH6101 in R/R AML (Business Wire)
May-23-23 01:00AM	Innate Pharma to Participate in Upcoming Investor Conferences (Business Wire)
May-15-23 01:00AM	Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress (Business Wire)
May-12-23 04:00PM	Outcome of Innate Pharmas 2023 Annual General Meeting (Business Wire)
May-10-23 01:00AM	Innate Pharma Reports First Quarter 2023 Financial Results and Business Update (Business Wire)
May-09-23 01:00AM	Number of shares and voting rights of Innate Pharma as of May 1, 2023 (Business Wire)
May-03-23 01:00AM	Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting (Business Wire)
01:00AM	Innate Pharma Announces Conference Call and Webcast for Q1 Business Update (Business Wire)
Apr-26-23 04:50PM	Innate Pharma Establishes a New At-The-Market ("ATM") Program on Nasdaq (Business Wire)
Apr-21-23 01:00AM	Innate Pharma to Participate in Upcoming Investor Conference (Business Wire)
Apr-18-23 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023 (Business Wire)
Apr-07-23 01:00AM	Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023 (Business Wire)
Apr-06-23 01:00AM	Innate Pharma Files Its 2022 Universal Registration Document (Document denregistrement universel) and 2022 Annual Report on Form 20-F (Business Wire)
Apr-03-23 01:00AM	Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program (Business Wire) +10.53%
Mar-23-23 02:00AM	Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update (Business Wire) -11.88%
Mar-20-23 02:00AM	Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023 (Business Wire)
Mar-16-23 02:00AM	Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results (Business Wire) -5.46%
Mar-13-23 02:00AM	Innate Pharma Provides Update on Silicon Valley Bank Exposure (Business Wire)
Feb-21-23 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of February 1, 2023 (Business Wire)
Feb-07-23 01:00AM	Innate Pharma to Participate in Upcoming Investor Conferences (Business Wire)
Jan-25-23 01:00AM	Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers (Business Wire)
Jan-16-23 01:00AM	Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology (Business Wire)
Dec-19-22 01:00AM	Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology (Business Wire) +39.47%
Dec-12-22 11:35AM	Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer (Benzinga)
Dec-10-22 10:00AM	Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022 (Business Wire)
Dec-09-22 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022 (Business Wire)

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Herve Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournie, and Francois Romagne on September 23, 1999 and is headquartered in Marseille, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IPHA

Innate Pharma ADR

Upgrade your FINVIZ experience